Report says CMOs without U.S. facilities risk being left out of 'hot' market

A new report from CPhI of the U.S. market says that international API and drug manufacturers need to consider investing in U.S. manufacturing sites as drugmakers look to source products in the U.S. because of concerns over quality in some other countries. It says that "for contract manufacturing, the U.S. market is now as hot as it has been at any other time in the last 10 years, with a scramble occurring across international players to get a domestic manufacturing foothold in the market," especially in specialized areas like biologics. Release

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.